Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Active not recruiting 3

Sponsor Class

OTHER 1NIH 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Gynecologic 1

Conditions

Prostatic Neoplasms 54Carcinoma, Non-Small-Cell Lung 33Lung Neoplasms 30Breast Neoplasms 29Glioblastoma 23Multiple Myeloma 21Glioma 20Lymphoma 19Pancreatic Neoplasms 17Lymphoma, Large B-Cell, Diffuse 17Carcinoma, Renal Cell 17Urinary Bladder Neoplasms 16Brain Neoplasms 14Sarcoma 13Squamous Cell Carcinoma of Head and Neck 12Rectal Neoplasms 11Neoplasm Metastasis 11Melanoma 11Lymphoma, Non-Hodgkin 11Thyroid Neoplasms 10Ovarian Neoplasms 10Oropharyngeal Neoplasms 10Neuroblastoma 9Mouth Neoplasms 9Medulloblastoma 9Lymphoma, Follicular 9Ependymoma 9Colorectal Neoplasms 9Central Nervous System Neoplasms 9Astrocytoma 9

Interventions

Fluorouracil 6Cisplatin 4Radiotherapy, Intensity-Modulated 3Radiotherapy 3Magnetic Resonance Spectroscopy 3Capecitabine 3dehydroftorafur 2Specimen Handling 2Mitomycin 2Cetuximab 2toripalimab 1rocakinogene sifuplasmid 1pembrolizumab 1durvalumab 1atezolizumab 1Vaccines 1VGX-3100 1Taxes 1Radiosurgery 1Radiation 1Platinum 1Paclitaxel 1Nivolumab 1Mitozytrex 1Mitomycins 1MEDI0457 1Ipilimumab 1Immunoglobulin G 1Fluorodeoxyglucose F18 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Anal Canal Carcinoma × Magnetic Resonance Spectroscopy × Clear all
NCT02314169 2026-05-28

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
143 enrolled 16 charts
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

NCT04166318 2026-05-05

Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
252 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

NCT03403465 2026-02-27

Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers

Duke University

Phase 2 Active not recruiting
90 enrolled
GastrointestinalGynecologic

Anal Canal Carcinoma, Uterine Cervical Neoplasms, Esophageal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡